233. Wolfram syndrome Clinical trials / Disease details
Clinical trials : 9 / Drugs : 15 - (DrugBank : 7) / Drug target genes : 11 - Drug target pathways : 41
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04940572 (ClinicalTrials.gov) | September 1, 2021 | 11/5/2021 | Efficacy Study of Daily Administration of VPA in Patients Affected by Wolfram Syndrome | AUDIOWOLF: A Phase II, Open-label, Efficacy Study of Daily Administration of Sodium Valproate in Patients Clinically Affected by Wolfram Syndrome Due to Monogenic Mutation. | Wolfram Syndrome | Drug: Depakine | Centre d'Etude des Cellules Souches | Genethon | Not yet recruiting | 13 Years | N/A | All | 23 | Phase 2 | NULL |
| 2 | EUCTR2020-004594-43-FR (EUCTR) | 11/03/2021 | AUDIOWOLF: A phase II, open-label, efficacy study of daily administration of sodium valproate in patients clinically affected by Wolfram syndrome due to monogenic mutation | AUDIOWOLF: A phase II, open-label, efficacy study of daily administration of sodium valproate in patients clinically affected by Wolfram syndrome due to monogenic mutation - AUDIOWOLF | Wolfram syndrome MedDRA version: 20.0;Level: PT;Classification code 10078338;Term: Wolfram syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: DEPAKINE CHRONO® 500 mg Product Name: DEPAKINE CHRONO 500 mg | CECS/I-Stem | NULL | NA | Female: yes Male: yes | 23 | Phase 2 | France |